Abstract:The last decade (2013–2023) has seen unprecedented successes in the clinical translation of therapeutic antisense oligonucleotides (ASOs). Eight such molecules have been granted marketing approval by the United States Food and Drug Administration (US FDA) during the decade, after the first ASO drug, fomivirsen, was approved much earlier, in 1998. Splice-modulating ASOs have also been developed for the therapy of inborn errors of metabolism (IEMs), due to their ability to redirect aberrant splicing caused by mutations, thus recovering the expression of normal transcripts, and correcting the deficiency of functional proteins. The feasibility of treating IEM patients with splice-switching ASOs has been supported by FDA permission (2018) of the first "N-of-1" study of milasen, an investigational ASO drug for Batten disease. Although for IEM, owing to the rarity of individual disease and/or pathogenic mutation, only a low number of patients may be treated by ASOs that specifically suppress the aberrant splicing pattern of mutant precursor mRNA (pre-mRNA), splice-switching ASOs represent superior individualized molecular therapeutics for IEM. In this work, we first summarize the ASO technology with respect to its mechanisms of action, chemical modifications of nucleotides, and rational design of modified oligonucleotides; following that, we precisely provide a review of the current understanding of developing splice-modulating ASO-based therapeutics for IEM. In the concluding section, we suggest potential ways to improve and/or optimize the development of ASOs targeting IEM.

Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application

Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases

Synthesis, Biophysical and Biological Evaluation of Splice-Switching Oligonucleotides with Multiple LNA-Phosphothiotriester Backbones

A framework for individualized splice-switching oligonucleotide therapy

Splice-switching antisense oligonucleotides for pediatric neurological disorders

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

Development and validation of AI/ML derived splice-switching oligonucleotides

Specificity, synergy, and mechanisms of splice-modifying drugs

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons

OpenASO: RNA Rescue—designing splice-modulating antisense oligonucleotides through community science

Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model

RNA splicing process analysis for identifying antisense oligonucleotide inhibitors with padlock probe-based isothermal amplification.

Synthesis and Evaluation of 4′‐C‐(S) and 4′‐C‐(R)‐2‐Aminopropoxy−Thymidine‐Modified DNAs for Thermal Stability, RNase H Digestion, and Nuclease Resistance

Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model

Mechanistic Insights into ASO-RNA Complexation: Advancing Antisense Oligonucleotide Design Strategies

Antisense oligonucleotides: a novel Frontier in pharmacological strategy

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene

Going nuclear: Improved antisense oligonucleotide activity through conjugation with a nuclear importer

CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements

RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides

Dendrimer Conjugates for Light-Activated Delivery of Antisense Oligonucleotides